At high blood glucose, there is increased expression of NLRP3, ASC, and caspase-1 protein; however, when treated with loganin, there was upregulation of these proteins that influences by decreasing NF-κB phosphorylation and reducing oxidative stress, which may suggest a potential as a therapeutics in peripheral diabetic neuropathy [41] by improving insulin resistance, decreasing mRNA and protein levels of the proinflammatory factors IL-1 and TNF, and treating diabetes-associated complications [86]. The gene discussed is NFKB1; the disease is Insulin resistance.